Is Rasagiline on the market?

Rasagiline was approved in Europe in 2005, under the supervision of the U.S. Food and Drug Administration (FDA) in 2006, and was approved by the National Medical Products Administration in China in 2017 for the symptom management of idiopathic Parkinson's disease, as initial monotherapy and adjuvant therapy with levodopa.

Rasagiline is an irreversible monoamine oxidase inhibitor thought to be related to its MAO-B inhibitory activity, MAO is a flavin-containing enzyme that regulates the metabolic degradation of catecholamines and serotonin in the central nervous system and peripheral tissues. Rasagiline is a potent, selective and irreversible inhibitor of monoamine oxidase type B (MAO-B). At recommended therapeutic doses, rasagiline has also been shown to be a potent and irreversible inhibitor of MAO-B in platelets. The selectivity of rasagiline for inhibiting only MAO-B (but not MAO-A) in humans and the sensitivity to tyramine during treatment with any dose of rasagiline have not been fully characterized to avoid restriction of dietary tyramine and amines contained in the drug.

The original drug of rasagiline marketed in China has entered the category of Class B medical insurance. The common name is rasagiline mesylate tablets, and the specification isThe price of each box of 1mg*14 tablets may be around 600 yuan. The price of the Turkish version of rasagiline's original drug, 1mg*30 tablets, per box sold overseas may be around RMB 310 (the price may fluctuate due to exchange rates). There are also generic drugs produced in other countries. The price of a box of 1mg*100 tablets produced by an Indian pharmaceutical factory may be around RMB 240 (the price may fluctuate due to the exchange rate). The pharmaceutical ingredients of generic drugs are basically the same as those of domestic and foreign original drugs. For specific prices and drug information, please consult Yaode Medical Consultants.